CO7020871A2 - Anticuerpos anti-il-36r - Google Patents

Anticuerpos anti-il-36r

Info

Publication number
CO7020871A2
CO7020871A2 CO14103887A CO14103887A CO7020871A2 CO 7020871 A2 CO7020871 A2 CO 7020871A2 CO 14103887 A CO14103887 A CO 14103887A CO 14103887 A CO14103887 A CO 14103887A CO 7020871 A2 CO7020871 A2 CO 7020871A2
Authority
CO
Colombia
Prior art keywords
antibodies
Prior art date
Application number
CO14103887A
Other languages
English (en)
Inventor
Su-Ellen Brown
Keith Canada
Lukasz Chlewicki
Michael Howell
Detlev Mennerich
Woska Joseph Robert Jr
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47215803&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7020871(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO7020871A2 publication Critical patent/CO7020871A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
CO14103887A 2011-11-16 2014-05-14 Anticuerpos anti-il-36r CO7020871A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161560554P 2011-11-16 2011-11-16
US201261644111P 2012-05-08 2012-05-08
US201261713713P 2012-10-15 2012-10-15

Publications (1)

Publication Number Publication Date
CO7020871A2 true CO7020871A2 (es) 2014-08-11

Family

ID=47215803

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14103887A CO7020871A2 (es) 2011-11-16 2014-05-14 Anticuerpos anti-il-36r

Country Status (38)

Country Link
US (3) US9023995B2 (es)
EP (2) EP2780373B1 (es)
JP (3) JP6289375B2 (es)
KR (3) KR20200110476A (es)
CN (3) CN112812183A (es)
AP (1) AP2014007571A0 (es)
AR (1) AR089178A1 (es)
AU (1) AU2012339734B2 (es)
BR (1) BR112014011594B1 (es)
CA (1) CA2852994C (es)
CL (1) CL2014001123A1 (es)
CO (1) CO7020871A2 (es)
CY (1) CY1122278T1 (es)
DK (1) DK2780373T3 (es)
EA (1) EA031948B1 (es)
EC (1) ECSP14004976A (es)
ES (1) ES2755732T3 (es)
FI (1) FIC20230020I1 (es)
FR (1) FR23C1023I2 (es)
HR (1) HRP20191835T1 (es)
HU (2) HUE047437T2 (es)
IL (2) IL232100B (es)
LT (2) LT2780373T (es)
MX (1) MX347164B (es)
MY (1) MY195289A (es)
NL (1) NL301233I2 (es)
PE (1) PE20142041A1 (es)
PH (1) PH12014501108A1 (es)
PL (1) PL2780373T3 (es)
PT (1) PT2780373T (es)
RS (1) RS59248B1 (es)
SG (1) SG11201402283PA (es)
SI (1) SI2780373T1 (es)
TW (1) TWI573804B (es)
UA (1) UA115540C2 (es)
UY (1) UY34456A (es)
WO (1) WO2013074569A1 (es)
ZA (1) ZA201402491B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
KR20200110476A (ko) 2011-11-16 2020-09-23 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
ES2812849T3 (es) 2012-02-24 2021-03-18 Abbvie Stemcentrx Llc Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
BR112016018408A2 (pt) * 2014-03-14 2017-12-26 Immutep Sas moléculas de anticorpo à lag-3 e usos das mesmas
RU2582569C2 (ru) * 2014-07-24 2016-04-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека, днк, кодирующая полноразмерный антагонист рецептора интерлейкина-36 человека с с-концевым полигистидиновым тагом, плазмидный экспрессионный вектор (варианты), штамм бактерий escherichia coli bl21 star[de3] (рет-il36raf), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 и штамм бактерий escherichia coli bl21 star[de3] (pet-il36raf-his), - продуцент полноразмерного рецепторного антагониста интерлейкина-36 с с-концевым полигистидиновым тагом
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
DK3283110T3 (da) * 2015-04-15 2022-05-23 Anaptysbio Inc Antistoffer rettet mod interleukin-36-receptor (il-36r)
US10723793B2 (en) * 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
JP2019537438A (ja) 2016-11-01 2019-12-26 アナプティスバイオ インコーポレイティッド Ｔｉｍ−３（ｔ細胞イムノグロブリンおよびムチンタンパク質３）に対する抗体
MA47206A (fr) 2017-01-09 2019-11-13 Tesaro Inc Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
WO2018183173A1 (en) * 2017-03-27 2018-10-04 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
EP3737366A4 (en) * 2018-01-08 2022-07-27 ChemoCentryx, Inc. METHOD OF TREATMENT OF GENERALIZED PUSTULOUS PSORIASIS WITH AN ANTAGONIST OF CCR6 OR CXCR2
JP7404256B2 (ja) * 2018-03-14 2023-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用
EP4183804A1 (en) * 2018-03-14 2023-05-24 Boehringer Ingelheim International GmbH Use of il-36r antibodies for treatment of inflammatory bowel disease
CN112638154B (zh) * 2018-07-16 2022-10-18 瑞泽恩制药公司 Ditra疾病的非人动物模型及其用途
EP3823989A2 (en) * 2018-07-16 2021-05-26 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
US20220267454A1 (en) 2018-08-16 2022-08-25 Cantargia Ab Anti-IL1RAP Antibody Compositions
AU2019349958A1 (en) * 2018-09-28 2021-05-06 Kyowa Kirin Co., Ltd. IL-36 antibodies and uses thereof
EA202191656A1 (ru) 2018-12-21 2021-10-26 23Эндми, Инк. Анти-il-36 антитела и способы их применения
BR112021010789A2 (pt) 2018-12-27 2021-08-31 Boehringer Ingelheim International Gmbh Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar
WO2020185479A1 (en) * 2019-03-08 2020-09-17 Boehringer Ingelheim International Gmbh Anti-il-36r antibody formulations
US20220162326A1 (en) * 2019-05-13 2022-05-26 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
JPWO2021112196A1 (es) * 2019-12-05 2021-06-10
AR120913A1 (es) * 2019-12-27 2022-03-30 Teijin Pharma Ltd Anticuerpo que inhibe específicamente la señalización de il-36r
TW202208433A (zh) 2020-05-19 2022-03-01 德商百靈佳殷格翰國際股份有限公司 用於治療異位性皮膚炎之抗ｉｌ－３６ｒ抗體
CN116745315A (zh) 2020-07-17 2023-09-12 勃林格殷格翰国际有限公司 用于治疗嗜中性皮肤病的抗il-36r抗体
WO2022026832A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
MX2023003723A (es) 2020-09-30 2023-04-24 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico.
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
EP4289863A1 (en) * 2020-12-17 2023-12-13 Shanghai Huaota Biopharmaceutical Co., Ltd. Bispecific antibody targeting il-17a and il-36r and application thereof
US20240084021A1 (en) 2021-01-08 2024-03-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022166977A1 (zh) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
TW202302644A (zh) 2021-03-04 2023-01-16 德商百靈佳殷格翰國際股份有限公司 治療gpp之方法
WO2022192531A2 (en) 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
CN117222668A (zh) * 2021-05-03 2023-12-12 勃林格殷格翰国际有限公司 制备spesolimab的方法
EP4357361A1 (en) * 2021-06-18 2024-04-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anti-il-36r antibody and use thereof
WO2023285362A1 (en) 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
US20230049147A1 (en) 2021-08-13 2023-02-16 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for the treatment of a fibrotic condition
WO2023052222A2 (en) 2021-09-28 2023-04-06 Boehringer Ingelheim International Gmbh System and method for assessing severity of neutrophilic dermatoses with visible skin manifestation
WO2023077091A1 (en) * 2021-10-28 2023-05-04 Abbvie Inc. Anti-amyloid beta antibodies and methods of using the same
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
PT1003861E (pt) 1997-08-01 2007-01-31 Schering Corp Proteínas de membrana de células de mamíferos;reagentes relacionados
HUP0300369A2 (hu) * 2000-04-11 2003-06-28 Genentech, Inc. Többértékű antitestek és alkalmazásuk
EP1627927A3 (en) * 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
US20040110930A1 (en) * 2002-10-03 2004-06-10 Reinl Stephen J. Multimeric protein engineering
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
MY169746A (en) * 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2438444T3 (es) * 2006-09-08 2014-01-16 Amgen, Inc Variantes de la familia de IL-1
EP2152750A1 (en) 2007-04-23 2010-02-17 Schering Corporation Anti-mdl-1 antibodies
EP2176294B1 (en) 2007-06-29 2015-05-20 Merck Sharp & Dohme Corp. Uses of mdl-1 antagonists
MX2011002153A (es) * 2008-08-28 2011-03-29 Wyeth Llc Usos de citocinas de las familias de interleucina-22, interleucina-17 e interleucina-1 en enfermedades autoinmunitarias.
KR20200110476A (ko) 2011-11-16 2020-09-23 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
DK3283110T3 (da) 2015-04-15 2022-05-23 Anaptysbio Inc Antistoffer rettet mod interleukin-36-receptor (il-36r)

Also Published As

Publication number Publication date
CA2852994C (en) 2023-02-14
TW201333037A (zh) 2013-08-16
ES2755732T3 (es) 2020-04-23
IL232100A0 (en) 2014-05-28
NL301233I2 (nl) 2023-09-13
NL301233I1 (es) 2023-06-07
IL232100B (en) 2020-04-30
US9023995B2 (en) 2015-05-05
LT2780373T (lt) 2019-09-25
EP2780373A1 (en) 2014-09-24
KR20140101738A (ko) 2014-08-20
CN104080808B (zh) 2016-11-16
UY34456A (es) 2013-05-31
AU2012339734A1 (en) 2014-04-24
MX347164B (es) 2017-04-18
RS59248B1 (sr) 2019-10-31
LTPA2023518I1 (es) 2023-06-12
KR102159109B1 (ko) 2020-09-23
US20130236471A1 (en) 2013-09-12
TWI573804B (zh) 2017-03-11
AP2014007571A0 (en) 2014-04-30
AU2012339734B2 (en) 2017-02-16
CN107007833A (zh) 2017-08-04
FR23C1023I1 (fr) 2023-07-21
JP2015500633A (ja) 2015-01-08
CN104080808A (zh) 2014-10-01
PH12014501108B1 (en) 2014-08-04
US20200231684A1 (en) 2020-07-23
EP3536710A1 (en) 2019-09-11
CN107007833B (zh) 2020-12-11
SI2780373T1 (sl) 2019-12-31
FR23C1023I2 (fr) 2024-03-29
JP2018093885A (ja) 2018-06-21
KR20190122877A (ko) 2019-10-30
HUS2300021I1 (hu) 2023-07-28
UA115540C2 (uk) 2017-11-27
HRP20191835T1 (hr) 2019-12-27
CN112812183A (zh) 2021-05-18
JP6719490B2 (ja) 2020-07-08
CA2852994A1 (en) 2013-05-23
PL2780373T3 (pl) 2020-03-31
MY195289A (en) 2023-01-12
ZA201402491B (en) 2021-09-29
BR112014011594A2 (pt) 2017-07-04
EA201400579A1 (ru) 2014-10-30
SG11201402283PA (en) 2014-06-27
EP2780373B1 (en) 2019-08-21
KR20200110476A (ko) 2020-09-23
PT2780373T (pt) 2019-11-27
IL272035A (en) 2020-02-27
CY1122278T1 (el) 2020-11-25
JP6289375B2 (ja) 2018-03-07
US20170298135A9 (en) 2017-10-19
EA031948B1 (ru) 2019-03-29
HUE047437T2 (hu) 2020-04-28
US20150203584A1 (en) 2015-07-23
BR112014011594B1 (pt) 2021-11-09
PE20142041A1 (es) 2014-12-18
JP2020156506A (ja) 2020-10-01
DK2780373T3 (da) 2019-11-04
WO2013074569A1 (en) 2013-05-23
CL2014001123A1 (es) 2015-01-23
NZ623425A (en) 2015-12-24
AR089178A1 (es) 2014-08-06
MX2014005759A (es) 2014-09-08
FIC20230020I1 (fi) 2023-06-01
KR102038310B1 (ko) 2019-11-01
PH12014501108A1 (en) 2014-08-04
ECSP14004976A (es) 2015-11-30
US10550189B2 (en) 2020-02-04

Similar Documents

Publication Publication Date Title
FR23C1023I2 (fr) Anticorps anti-il-36r
CO6811812A2 (es) Anticuerpo anti-b7-h3
DK2934584T3 (da) Anti-gdf15-antistoffer
DK3275892T3 (da) Præfusions-rsv-f-antigener
DK2850101T3 (da) Anti-FcRn-antistoffer
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
CR20140127A (es) Anticuerpo anti-abtcr
DK2769050T3 (da) Propsensor
BR112014000879A2 (pt) deflegmador
CO6791565A2 (es) Anticuerpos anti-notch1
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
CO6960543A2 (es) 2-tiopirimidinonas
DE102011100082A8 (de) Traygreifvorrichtung
DK2828292T3 (da) Jcv-neutraliserende antistoffer
DK3141251T3 (da) Koloskopi - forberedelse
DK3521315T3 (da) Anti-transglutaminase-2-antistoffer
DK2935330T3 (da) Anti-notch3-antistoffer
DE112011104936A5 (de) Stanzstauchniet
CO6841994A2 (es) Anticuerpos
DE112012000958A5 (de) Handsäge
DK2476953T3 (da) Fluidbedkedel
DE112012002458A5 (de) Hydrotransformator
DE112012000819A5 (de) Gurtbandfänger
DE112012005313A5 (de) Leuchtbild
DK2526750T3 (da) Høbjærgningsmaskine